Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season

•Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2).•Vaccine was effective in preventing illness, 39% against influenza B.•Infants showed no significant vaccine effectiveness.•The children who were immunized in two consecutive seasons were more likely to have influenz...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 36; no. 37; pp. 5510 - 5518
Main Authors Shinjoh, Masayoshi, Sugaya, Norio, Yamaguchi, Yoshio, Iibuchi, Noriko, Kamimaki, Isamu, Goto, Anna, Kobayashi, Hisato, Kobayashi, Yasuaki, Shibata, Meiwa, Tamaoka, Satoshi, Nakata, Yuji, Narabayashi, Atsushi, Nishida, Mitsuhiro, Hirano, Yasuhiro, Munenaga, Takeshi, Morita, Kumiko, Mitamura, Keiko, Takahashi, Takao
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 05.09.2018
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract •Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2).•Vaccine was effective in preventing illness, 39% against influenza B.•Infants showed no significant vaccine effectiveness.•The children who were immunized in two consecutive seasons were more likely to have influenza.•However, the influenza vaccine should be recommended every season for children. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE. Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination. During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29–46) against influenza A and 39% (95% CI, 18–54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05–2.38], adjusted odds ratio, 1.53 [95% CI, 0.99–2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season. VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children.
AbstractList •Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2).•Vaccine was effective in preventing illness, 39% against influenza B.•Infants showed no significant vaccine effectiveness.•The children who were immunized in two consecutive seasons were more likely to have influenza.•However, the influenza vaccine should be recommended every season for children. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE. Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination. During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29–46) against influenza A and 39% (95% CI, 18–54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05–2.38], adjusted odds ratio, 1.53 [95% CI, 0.99–2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season. VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children.
We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.OBJECTIVESWe assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.METHODSOur study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29-46) against influenza A and 39% (95% CI, 18-54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05-2.38], adjusted odds ratio, 1.53 [95% CI, 0.99-2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.RESULTSDuring the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29-46) against influenza A and 39% (95% CI, 18-54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05-2.38], adjusted odds ratio, 1.53 [95% CI, 0.99-2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children.CONCLUSIONSVE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children.
We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE. Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination. During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29-46) against influenza A and 39% (95% CI, 18-54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05-2.38], adjusted odds ratio, 1.53 [95% CI, 0.99-2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season. VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children.
We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.Our study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.During the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29–46) against influenza A and 39% (95% CI, 18–54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05–2.38], adjusted odds ratio, 1.53 [95% CI, 0.99–2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.VE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children.
Highlights•Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2). •Vaccine was effective in preventing illness, 39% against influenza B. •Infants showed no significant vaccine effectiveness. •The children who were immunized in two consecutive seasons were more likely to have influenza. •However, the influenza vaccine should be recommended every season for children.
ObjectivesWe assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In addition, we estimated the impact of repeated vaccination in children on VE.MethodsOur study for VEs in preventing influenza and admission due to influenza were conducted according to a test-negative case-control design (TNCC) based on influenza rapid diagnostic test results. We also analyzed the VE by vaccine status in the current and previous seasons for the impact of repeated vaccination.ResultsDuring the 2016/17 season, the quadrivalent IIV was used in Japan. The adjusted VE in preventing influenza illness was 38% (95% CI, 29–46) against influenza A and 39% (95% CI, 18–54) against influenza B. Infants showed no significant VE. The VE in preventing hospitalization was not demonstrated. For the analysis of repeated vaccination, the vaccine was effective only when immunization occurred in the current season. The children who were immunized in two consecutive seasons were more likely to develop influenza compared to those immunized in the current season only (odds ratio, 1.58 [95% CI, 1.05–2.38], adjusted odds ratio, 1.53 [95% CI, 0.99–2.35]). However, the odds ratio of repeated vaccination was not significant when the analysis excluded those who developed influenza in the previous season.ConclusionsVE in children in the 2016/17 season was similar to values previously reported. Repeated vaccination interfered with the VE against any influenza infection in the 2016/17 season. The results of our study suggest that decreased VE by repeat vaccination phenomenon was associated with immunity by influenza infection in the previous season. However, the influenza vaccine should be recommended every season for children.
Author Iibuchi, Noriko
Mitamura, Keiko
Munenaga, Takeshi
Tamaoka, Satoshi
Sugaya, Norio
Kobayashi, Hisato
Yamaguchi, Yoshio
Shibata, Meiwa
Goto, Anna
Kobayashi, Yasuaki
Nakata, Yuji
Takahashi, Takao
Kamimaki, Isamu
Nishida, Mitsuhiro
Shinjoh, Masayoshi
Hirano, Yasuhiro
Narabayashi, Atsushi
Morita, Kumiko
Author_xml – sequence: 1
  givenname: Masayoshi
  surname: Shinjoh
  fullname: Shinjoh, Masayoshi
  organization: Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
– sequence: 2
  givenname: Norio
  surname: Sugaya
  fullname: Sugaya, Norio
  email: sugaya-n@za2.so-net.ne.jp
  organization: Department of Pediatrics, Keiyu Hospital, Yokohama, Kanagawa, Japan
– sequence: 3
  givenname: Yoshio
  surname: Yamaguchi
  fullname: Yamaguchi, Yoshio
  organization: Institute of Clinical Research Department of Infection & Allergy, National Hospital Organization Tochigi Medical Center, Utsunomiya, Tochigi, Japan
– sequence: 4
  givenname: Noriko
  surname: Iibuchi
  fullname: Iibuchi, Noriko
  organization: Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan
– sequence: 5
  givenname: Isamu
  surname: Kamimaki
  fullname: Kamimaki, Isamu
  organization: Department of Pediatrics, National Hospital Organization Saitama National Hospital, Wako, Saitama, Japan
– sequence: 6
  givenname: Anna
  surname: Goto
  fullname: Goto, Anna
  organization: Department of Pediatrics, Ota Memorial Hospital, Ota, Gunma, Japan
– sequence: 7
  givenname: Hisato
  surname: Kobayashi
  fullname: Kobayashi, Hisato
  organization: Department of Pediatrics, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochigi, Japan
– sequence: 8
  givenname: Yasuaki
  surname: Kobayashi
  fullname: Kobayashi, Yasuaki
  organization: Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, Ashikaga, Tochigi, Japan
– sequence: 9
  givenname: Meiwa
  surname: Shibata
  fullname: Shibata, Meiwa
  organization: Division of Pediatrics, Yokohama Rosai Hospital, Yokohama, Japan
– sequence: 10
  givenname: Satoshi
  surname: Tamaoka
  fullname: Tamaoka, Satoshi
  organization: Department of Pediatrics, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochgi, Japan
– sequence: 11
  givenname: Yuji
  surname: Nakata
  fullname: Nakata, Yuji
  organization: Department of Pediatrics, Nippon Kokan Hospital, Kawasaki, Kanagawa, Japan
– sequence: 12
  givenname: Atsushi
  surname: Narabayashi
  fullname: Narabayashi, Atsushi
  organization: Kawasaki Municipal Kawasaki Hospital, Kawasaki, Kanagawa, Japan
– sequence: 13
  givenname: Mitsuhiro
  surname: Nishida
  fullname: Nishida, Mitsuhiro
  organization: Department of Pediatrics, Shizuoka City Shimizu Hospital, Shizuoka, Japan
– sequence: 14
  givenname: Yasuhiro
  surname: Hirano
  fullname: Hirano, Yasuhiro
  organization: Department of Pediatrics, Hiratsuka City Hospital, Hiratsuka, Kanagawa, Japan
– sequence: 15
  givenname: Takeshi
  surname: Munenaga
  fullname: Munenaga, Takeshi
  organization: Department of Pediatrics, Ota Memorial Hospital, Ota, Gunma, Japan
– sequence: 16
  givenname: Kumiko
  surname: Morita
  fullname: Morita, Kumiko
  organization: Department of Pediatrics, Hiratsuka City Hospital, Hiratsuka, Kanagawa, Japan
– sequence: 17
  givenname: Keiko
  surname: Mitamura
  fullname: Mitamura, Keiko
  organization: Department of Pediatrics, Eiju General Hospital, Tokyo, Japan
– sequence: 18
  givenname: Takao
  surname: Takahashi
  fullname: Takahashi, Takao
  organization: Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30093289$$D View this record in MEDLINE/PubMed
BookMark eNqNkl2LEzEUhoOsuB_6E5SAN960npPJTDKIiix-LCx4oYJ3Ic2ccVOnmW4yU-j-ejPbuhcFqZCQkDzvy-G855ydhD4QY88R5ghYvV7ON9Y5H2guAPUc1Byq8hE7Q62KmShRn7AzEJWcSYSfp-w8pSUAlAXWT9hpAVAXQtdn7O4qWDf4jR2o4T603UjhzvK9N6e2pembAqXEbWjyzst22-QT71seaU332p3CDr4PvO0jdze-ayIF3ozRh198uCEupsJR8UQ29eEpe9zaLtGz_XnBfnz6-P3yy-z66-eryw_XM1cBDjOrWtUoKYXEAtC5hSiUq4UuZVUtZGnb_FCDynfboHS6KBGhlbqqXaO1q4sL9mrnu4797UhpMCufHHWdDdSPyQjEqhZSCXkcBa1KXReyzOjLA3TZjzF3ZqJqKbRWoDL1Yk-NixU1Zh39ysat-RtABsod4GKfUqT2AUEwU9BmafZhmCloA8rkoLPuzYHO-eG--0O0vjuqfr9TU-77xlM0yXkKjhofc96m6f1Rh3cHDq7zwTvb_aYtpYdeoEnCgPk2jeI0iagLBCUhG7z9t8F_FPAHbC3vTA
CitedBy_id crossref_primary_10_1097_EDE_0000000000001116
crossref_primary_10_1016_j_vaccine_2019_05_090
crossref_primary_10_1272_jnms_JNMS_2022_89_102
crossref_primary_10_1038_s41541_019_0123_7
crossref_primary_10_3390_vaccines7020053
crossref_primary_10_3390_v11090868
crossref_primary_10_1186_s12879_022_07898_y
crossref_primary_10_1016_j_vaccine_2022_03_047
crossref_primary_10_1007_s00705_024_06210_4
crossref_primary_10_1371_journal_pone_0249005
crossref_primary_10_3389_fimmu_2020_568978
crossref_primary_10_1016_j_vaccine_2024_02_006
crossref_primary_10_1017_S0950268820002058
crossref_primary_10_1016_j_vaccine_2022_07_002
crossref_primary_10_1016_j_vaccine_2024_126241
crossref_primary_10_3390_vaccines9121447
crossref_primary_10_1080_21645515_2019_1677438
crossref_primary_10_1080_14760584_2020_1711056
crossref_primary_10_37191_Mapsci_2582_4333_3_5__085
crossref_primary_10_1016_j_vaccine_2020_02_049
crossref_primary_10_1093_infdis_jiz434
crossref_primary_10_1080_21645515_2025_2468074
crossref_primary_10_1016_j_jiac_2021_08_020
crossref_primary_10_1016_j_vaccine_2024_05_034
crossref_primary_10_1016_S2213_2600_22_00266_1
crossref_primary_10_1371_journal_pone_0256165
crossref_primary_10_1016_j_jiac_2024_06_023
crossref_primary_10_1016_S1245_1789_23_48777_X
crossref_primary_10_3390_ijerph16061078
crossref_primary_10_1016_j_vaccine_2022_04_033
Cites_doi 10.1093/cid/ciu680
10.1093/cid/cix209
10.1371/journal.pone.0136539
10.7326/M17-0848
10.1016/j.jinf.2011.06.008
10.1093/infdis/jit091
10.1093/infdis/jix055
10.1371/journal.pone.0088813
10.1080/14760584.2017.1334554
10.1016/j.vaccine.2018.01.024
10.2807/1560-7917.ES.2016.21.42.30377
10.1111/irv.12565
10.1038/s41598-017-14536-0
10.1007/s10156-011-0288-0
10.1093/infdis/jiy027
10.2807/1560-7917.ES.2017.22.44.17-00306
10.1186/s12916-017-0919-0
10.15585/mmwr.rr6602a1
10.1093/cid/cix461
10.1093/infdis/jit263
10.2807/1560-7917.ES.2017.22.7.30464
10.15585/mmwr.mm6606a3
10.2807/1560-7917.ES.2016.21.7.30139
10.1093/cid/ciw176
ContentType Journal Article
Copyright 2018
Copyright © 2018. Published by Elsevier Ltd.
Copyright Elsevier Limited Sep 5, 2018
Copyright_xml – notice: 2018
– notice: Copyright © 2018. Published by Elsevier Ltd.
– notice: Copyright Elsevier Limited Sep 5, 2018
CorporateAuthor on behalf of the Keio Pediatric Influenza Research Group
Keio Pediatric Influenza Research Group
CorporateAuthor_xml – name: on behalf of the Keio Pediatric Influenza Research Group
– name: Keio Pediatric Influenza Research Group
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7RV
7T2
7T5
7U9
7X7
7XB
88C
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9-
K9.
KB0
LK8
M0R
M0S
M0T
M1P
M2O
M7N
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
7S9
L.6
DOI 10.1016/j.vaccine.2018.07.065
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Nursing & Allied Health Database
Health and Safety Science Abstracts (Full archive)
Immunology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
Proquest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
Consumer Health Database
ProQuest Health & Medical Collection
Healthcare Administration Database
Medical Database
Research Library
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Research Library
Health & Safety Science Abstracts
ProQuest Public Health
ProQuest Central Basic
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
ProQuest Medical Library
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE

AGRICOLA

Research Library Prep
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Veterinary Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2518
EndPage 5518
ExternalDocumentID 30093289
10_1016_j_vaccine_2018_07_065
S0264410X18310740
1_s2_0_S0264410X18310740
Genre Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
53G
5RE
5VS
7-5
71M
7RV
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAHBH
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABKYH
ABMAC
ABMZM
ABRWV
ABUWG
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACPRK
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEUYN
AEVXI
AEXOQ
AFKRA
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGGSO
AGUBO
AGYEJ
AHMBA
AIEXJ
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AQUVI
AXJTR
AZQEC
BBNVY
BENPR
BHPHI
BKEYQ
BKNYI
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
CCPQU
CJTIS
CNWQP
CS3
DWQXO
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
GNUQQ
GUQSH
HCIFZ
HMCUK
IHE
J1W
K9-
KOM
L7B
LK8
LUGTX
LW9
M0R
M0T
M1P
M29
M2O
M41
M7P
MO0
N9A
NAPCQ
O-L
O9-
O9~
OAUVE
OK0
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PUEGO
Q38
ROL
RPZ
SAB
SCC
SDF
SDG
SDP
SES
SNL
SPCBC
SSH
SSI
SSZ
T5K
UKHRP
UV1
WH7
WOW
Z5R
~G-
.GJ
29Q
3V.
AACTN
AAQXK
ABWVN
ABXDB
ACRPL
ADMUD
ADNMO
ADVLN
AFCTW
AFJKZ
AFKWA
AGHFR
AHHHB
AJOXV
ALIPV
AMFUW
ASPBG
AVWKF
AZFZN
FEDTE
FGOYB
G-2
HEJ
HLV
HMG
HMK
HMO
HVGLF
HX~
HZ~
R2-
RIG
SAE
SEW
SIN
SVS
WUQ
XPP
ZGI
ZXP
AAIAV
ABLVK
ABYKQ
AESVU
EFLBG
LCYCR
QYZTP
AAYXX
ACMHX
ADSLC
AGQPQ
AGRNS
AGWPP
AIGII
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T2
7T5
7U9
7XB
8FK
C1K
H94
K9.
M7N
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
7S9
L.6
ID FETCH-LOGICAL-c601t-a7f7d744241301ccb237c9285466b45afb239076b4ad14c835110f4869cd88c93
IEDL.DBID 7X7
ISSN 0264-410X
1873-2518
IngestDate Thu Jul 10 18:51:28 EDT 2025
Tue Aug 05 11:01:16 EDT 2025
Wed Aug 13 08:07:29 EDT 2025
Mon Jul 21 05:59:16 EDT 2025
Tue Jul 01 01:06:42 EDT 2025
Thu Apr 24 23:08:33 EDT 2025
Fri Feb 23 02:47:37 EST 2024
Sun Feb 23 10:19:35 EST 2025
Tue Aug 26 16:40:39 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 37
Keywords Hospitalization
Repeated vaccination
Effectiveness
Children
Test-negative case control design
Influenza vaccine
Language English
License Copyright © 2018. Published by Elsevier Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c601t-a7f7d744241301ccb237c9285466b45afb239076b4ad14c835110f4869cd88c93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 30093289
PQID 2094288707
PQPubID 105530
PageCount 9
ParticipantIDs proquest_miscellaneous_2116924724
proquest_miscellaneous_2087589345
proquest_journals_2094288707
pubmed_primary_30093289
crossref_primary_10_1016_j_vaccine_2018_07_065
crossref_citationtrail_10_1016_j_vaccine_2018_07_065
elsevier_sciencedirect_doi_10_1016_j_vaccine_2018_07_065
elsevier_clinicalkeyesjournals_1_s2_0_S0264410X18310740
elsevier_clinicalkey_doi_10_1016_j_vaccine_2018_07_065
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-09-05
PublicationDateYYYYMMDD 2018-09-05
PublicationDate_xml – month: 09
  year: 2018
  text: 2018-09-05
  day: 05
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
– name: Kidlington
PublicationTitle Vaccine
PublicationTitleAlternate Vaccine
PublicationYear 2018
Publisher Elsevier Ltd
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Limited
References Martinez-Baz, Casado, Navascues, Diaz-Gonzalez, Aguinaga, Barrado (b0095) 2017; 215
WHO. Influenza Laboratory Surveillance Information. Data source: FluNet
Belongia, Skowronski, McLean, Chambers, Sundaram, De Serres (b0085) 2017; 16
Sakai-Tagawa, Yamayoshi, Kawakami, Le, Uchida, Saito (b0105) 2017; 7
The National Institute of Infectious Diseases. Influenza 2016/17 season, Japan [In Japanese].
Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horvath JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill 2016;21:pii=30139.
Sugaya, Shinjoh, Kawakami, Yamaguchi, Yoshida, Baba (b0040) 2016; 21
Merckx, Wali, Schiller, Caya, Gore, Chartrand (b0140) 2017; 167
WHO. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS)
Global Influenza Surveillance and Response System (GISRS)
Grohskopf, Sokolow, Broder, Walter, Bresee, Fry (b0065) 2017; 66
McLean, Thompson, Sundaram, Meece, McClure, Friedrich (b0080) 2014; 59
Ramsay, Buchan, Stirling, Cowling, Feng, Kwong (b0100) 2017; 15
Chiu, Kwan, Feng, Wong, Leung, Chan (b0135) 2018
2017.
Suzuki, Minh le, Yoshimine, Inoue, Yoshida, Morimoto (b0145) 2014; 9
Skowronski, Chambers, Sabaiduc, De Serres, Winter, Dickinson (b0075) 2016; 63
Flannery, Chung, Thaker, Monto, Martin, Belongia (b0025) 2017; 66
FluNet; 2017.
CDC. Vaccine effectiveness – how well does the flu vaccine work?
Cheng, Macartney, Waterer, Kotsimbos, Kelly, Blyth (b0090) 2017; 64
Sugaya, Shinjoh, Mitamura, Takahashi (b0050) 2011; 63
Sugaya, Shinjoh, Nakata, Tsunematsu, Yamaguchi, Komiyama (b0045) 2018; 36
Domachowske, Pankow-Culot, Bautista, Feng, Claeys, Peeters (b0115) 2013; 207
The National Institute of Infectious Diseases. Influenza vaccine coverage rate by age and age group, Japan [In Japanese].
The National Institute of Infectious Diseases N. Influenza virus isolation, 2013/14-2017/18, Japan [In Japanese].
The National Institute of Infectious Diseases. Influenza 2016/17 season, Japan.
.
Langley, Carmona Martinez, Chatterjee, Halperin, McNeil, Reisinger (b0120) 2013; 208
Shinjoh, Sugaya, Yamaguchi, Tomidokoro, Sekiguchi, Mitamura (b0035) 2015; 10
Pebody, Warburton, Ellis, Andrews, Potts, Cottrell (b0030) 2017; 22
Kissling, Rondy (b0110) 2017; 22
Sugaya (b0055) 2011; 17
Bruning, Leeflang, Vos, Spijker, de Jong, Wolthers (b0150) 2017; 65
2018.
Suzuki (10.1016/j.vaccine.2018.07.065_b0145) 2014; 9
Sugaya (10.1016/j.vaccine.2018.07.065_b0055) 2011; 17
10.1016/j.vaccine.2018.07.065_b0005
McLean (10.1016/j.vaccine.2018.07.065_b0080) 2014; 59
Martinez-Baz (10.1016/j.vaccine.2018.07.065_b0095) 2017; 215
Sugaya (10.1016/j.vaccine.2018.07.065_b0045) 2018; 36
Cheng (10.1016/j.vaccine.2018.07.065_b0090) 2017; 64
Shinjoh (10.1016/j.vaccine.2018.07.065_b0035) 2015; 10
Langley (10.1016/j.vaccine.2018.07.065_b0120) 2013; 208
Merckx (10.1016/j.vaccine.2018.07.065_b0140) 2017; 167
Ramsay (10.1016/j.vaccine.2018.07.065_b0100) 2017; 15
10.1016/j.vaccine.2018.07.065_b0070
10.1016/j.vaccine.2018.07.065_b0010
Belongia (10.1016/j.vaccine.2018.07.065_b0085) 2017; 16
Skowronski (10.1016/j.vaccine.2018.07.065_b0075) 2016; 63
Kissling (10.1016/j.vaccine.2018.07.065_b0110) 2017; 22
10.1016/j.vaccine.2018.07.065_b0015
10.1016/j.vaccine.2018.07.065_b0155
Sugaya (10.1016/j.vaccine.2018.07.065_b0040) 2016; 21
Bruning (10.1016/j.vaccine.2018.07.065_b0150) 2017; 65
Chiu (10.1016/j.vaccine.2018.07.065_b0135) 2018
Pebody (10.1016/j.vaccine.2018.07.065_b0030) 2017; 22
Sakai-Tagawa (10.1016/j.vaccine.2018.07.065_b0105) 2017; 7
Flannery (10.1016/j.vaccine.2018.07.065_b0025) 2017; 66
Sugaya (10.1016/j.vaccine.2018.07.065_b0050) 2011; 63
10.1016/j.vaccine.2018.07.065_b0060
Grohskopf (10.1016/j.vaccine.2018.07.065_b0065) 2017; 66
10.1016/j.vaccine.2018.07.065_b0020
Domachowske (10.1016/j.vaccine.2018.07.065_b0115) 2013; 207
10.1016/j.vaccine.2018.07.065_b0125
References_xml – reference: WHO. Influenza Laboratory Surveillance Information. Data source: FluNet (
– reference: ), Global Influenza Surveillance and Response System (GISRS)
– reference: Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horvath JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill 2016;21:pii=30139.
– reference: The National Institute of Infectious Diseases. Influenza vaccine coverage rate by age and age group, Japan [In Japanese].
– volume: 66
  start-page: 167
  year: 2017
  end-page: 171
  ident: b0025
  article-title: Interim estimates of 2016–17 seasonal influenza vaccine effectiveness – United States, February 2017
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 215
  start-page: 847
  year: 2017
  end-page: 855
  ident: b0095
  article-title: Effect of repeated vaccination with the same vaccine component against 2009 pandemic influenza A(H1N1) virus
  publication-title: J Infect Dis
– volume: 10
  start-page: e0136539
  year: 2015
  ident: b0035
  article-title: Effectiveness of trivalent inactivated influenza vaccine in children estimated by a test-negative case-control design study based on influenza rapid diagnostic test results
  publication-title: PLoS One
– volume: 65
  start-page: 1026
  year: 2017
  end-page: 1032
  ident: b0150
  article-title: Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis
  publication-title: Clin Infect Dis
– volume: 16
  start-page: 1
  year: 2017
  end-page: 14
  ident: b0085
  article-title: Repeated annual influenza vaccination and vaccine effectiveness: review of evidence
  publication-title: Expert Rev Vaccines
– reference: The National Institute of Infectious Diseases N. Influenza virus isolation, 2013/14-2017/18, Japan [In Japanese].
– volume: 36
  start-page: 1063
  year: 2018
  end-page: 1071
  ident: b0045
  article-title: Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013–2016
  publication-title: Vaccine
– reference: The National Institute of Infectious Diseases. Influenza 2016/17 season, Japan.
– volume: 207
  start-page: 1878
  year: 2013
  end-page: 1887
  ident: b0115
  article-title: A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years
  publication-title: J Infect Dis
– volume: 208
  start-page: 544
  year: 2013
  end-page: 553
  ident: b0120
  article-title: Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children
  publication-title: J Infect Dis
– volume: 9
  start-page: e88813
  year: 2014
  ident: b0145
  article-title: Vaccine effectiveness against medically attended laboratory-confirmed influenza in Japan, 2011–2012 season
  publication-title: PLoS One
– volume: 15
  start-page: 159
  year: 2017
  ident: b0100
  article-title: The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis
  publication-title: BMC Med
– reference: . FluNet; 2017.
– volume: 66
  start-page: 1
  year: 2017
  end-page: 20
  ident: b0065
  article-title: Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2017–18 Influenza Season
  publication-title: MMWR Recomm Rep
– volume: 22
  year: 2017
  ident: b0110
  article-title: Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe
  publication-title: Euro Surveill
– reference: WHO. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS)
– volume: 63
  start-page: 288
  year: 2011
  end-page: 294
  ident: b0050
  article-title: Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children
  publication-title: J Infect
– volume: 17
  start-page: 595
  year: 2011
  end-page: 601
  ident: b0055
  article-title: Widespread use of neuraminidase inhibitors in Japan
  publication-title: J Infect Chemother
– reference: . 2018.
– reference: CDC. Vaccine effectiveness – how well does the flu vaccine work?
– volume: 7
  start-page: 14483
  year: 2017
  ident: b0105
  article-title: Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan
  publication-title: Sci Rep
– reference: ; 2017.
– reference: The National Institute of Infectious Diseases. Influenza 2016/17 season, Japan [In Japanese].
– volume: 64
  start-page: 1564
  year: 2017
  end-page: 1572
  ident: b0090
  article-title: Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenza
  publication-title: Clin Infect Dis
– reference: .
– volume: 21
  year: 2016
  ident: b0040
  article-title: Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan
  publication-title: Euro Surveill
– volume: 63
  start-page: 21
  year: 2016
  end-page: 32
  ident: b0075
  article-title: A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–2015 Season
  publication-title: Clin Infect Dis
– volume: 167
  start-page: 394
  year: 2017
  end-page: 409
  ident: b0140
  article-title: diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis
  publication-title: Ann Intern Med
– year: 2018
  ident: b0135
  article-title: Influenza vaccine effectiveness against influenza A(H3N2) hospitalizations in children in Hong Kong in a prolonged season, 2016/17
  publication-title: J Infect Dis
– volume: 59
  start-page: 1375
  year: 2014
  end-page: 1385
  ident: b0080
  article-title: Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons
  publication-title: Clin Infect Dis
– volume: 22
  year: 2017
  ident: b0030
  article-title: End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17
  publication-title: Euro Surveill
– volume: 59
  start-page: 1375
  year: 2014
  ident: 10.1016/j.vaccine.2018.07.065_b0080
  article-title: Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciu680
– ident: 10.1016/j.vaccine.2018.07.065_b0155
– volume: 64
  start-page: 1564
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0090
  article-title: Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenza
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cix209
– volume: 10
  start-page: e0136539
  year: 2015
  ident: 10.1016/j.vaccine.2018.07.065_b0035
  article-title: Effectiveness of trivalent inactivated influenza vaccine in children estimated by a test-negative case-control design study based on influenza rapid diagnostic test results
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0136539
– volume: 167
  start-page: 394
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0140
  article-title: diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis
  publication-title: Ann Intern Med
  doi: 10.7326/M17-0848
– volume: 63
  start-page: 288
  year: 2011
  ident: 10.1016/j.vaccine.2018.07.065_b0050
  article-title: Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children
  publication-title: J Infect
  doi: 10.1016/j.jinf.2011.06.008
– volume: 207
  start-page: 1878
  year: 2013
  ident: 10.1016/j.vaccine.2018.07.065_b0115
  article-title: A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jit091
– volume: 215
  start-page: 847
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0095
  article-title: Effect of repeated vaccination with the same vaccine component against 2009 pandemic influenza A(H1N1) virus
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jix055
– ident: 10.1016/j.vaccine.2018.07.065_b0060
– volume: 9
  start-page: e88813
  year: 2014
  ident: 10.1016/j.vaccine.2018.07.065_b0145
  article-title: Vaccine effectiveness against medically attended laboratory-confirmed influenza in Japan, 2011–2012 season
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0088813
– ident: 10.1016/j.vaccine.2018.07.065_b0005
– volume: 16
  start-page: 1
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0085
  article-title: Repeated annual influenza vaccination and vaccine effectiveness: review of evidence
  publication-title: Expert Rev Vaccines
  doi: 10.1080/14760584.2017.1334554
– volume: 36
  start-page: 1063
  year: 2018
  ident: 10.1016/j.vaccine.2018.07.065_b0045
  article-title: Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013–2016
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2018.01.024
– ident: 10.1016/j.vaccine.2018.07.065_b0015
– volume: 21
  year: 2016
  ident: 10.1016/j.vaccine.2018.07.065_b0040
  article-title: Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2016.21.42.30377
– ident: 10.1016/j.vaccine.2018.07.065_b0125
– ident: 10.1016/j.vaccine.2018.07.065_b0020
– ident: 10.1016/j.vaccine.2018.07.065_b0010
  doi: 10.1111/irv.12565
– volume: 7
  start-page: 14483
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0105
  article-title: Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-14536-0
– volume: 17
  start-page: 595
  year: 2011
  ident: 10.1016/j.vaccine.2018.07.065_b0055
  article-title: Widespread use of neuraminidase inhibitors in Japan
  publication-title: J Infect Chemother
  doi: 10.1007/s10156-011-0288-0
– year: 2018
  ident: 10.1016/j.vaccine.2018.07.065_b0135
  article-title: Influenza vaccine effectiveness against influenza A(H3N2) hospitalizations in children in Hong Kong in a prolonged season, 2016/17
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiy027
– volume: 22
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0030
  article-title: End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2017.22.44.17-00306
– volume: 15
  start-page: 159
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0100
  article-title: The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis
  publication-title: BMC Med
  doi: 10.1186/s12916-017-0919-0
– volume: 66
  start-page: 1
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0065
  article-title: Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2017–18 Influenza Season
  publication-title: MMWR Recomm Rep
  doi: 10.15585/mmwr.rr6602a1
– volume: 65
  start-page: 1026
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0150
  article-title: Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cix461
– volume: 208
  start-page: 544
  year: 2013
  ident: 10.1016/j.vaccine.2018.07.065_b0120
  article-title: Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jit263
– volume: 22
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0110
  article-title: Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2017.22.7.30464
– volume: 66
  start-page: 167
  year: 2017
  ident: 10.1016/j.vaccine.2018.07.065_b0025
  article-title: Interim estimates of 2016–17 seasonal influenza vaccine effectiveness – United States, February 2017
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6606a3
– ident: 10.1016/j.vaccine.2018.07.065_b0070
  doi: 10.2807/1560-7917.ES.2016.21.7.30139
– volume: 63
  start-page: 21
  year: 2016
  ident: 10.1016/j.vaccine.2018.07.065_b0075
  article-title: A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–2015 Season
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciw176
SSID ssj0005319
Score 2.4175932
Snippet •Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2).•Vaccine was effective in preventing illness, 39% against influenza...
Highlights•Vaccine was effective in preventing illness, 38% against influenza A (mostly H3N2). •Vaccine was effective in preventing illness, 39% against...
We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season. In...
ObjectivesWe assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age during the 2016/17 season....
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 5510
SubjectTerms Adolescent
Age
Allergy and Immunology
Case-Control Studies
Child
Child, Preschool
Children
Children & youth
Diagnostic systems
Effectiveness
Enrollments
Female
Hospitalization
Hospitalization - statistics & numerical data
Humans
Immunity
Immunization
Infant
Infants
Influenza
Influenza A
Influenza A Virus, H3N2 Subtype
Influenza B
Influenza B virus
Influenza vaccine
influenza vaccines
Influenza Vaccines - therapeutic use
Influenza, Human - prevention & control
Japan
Male
Maternal & child health
Odds Ratio
Patients
Repeated vaccination
Seasons
Test-negative case control design
Vaccination
Vaccine efficacy
Vaccines
Vaccines, Inactivated - therapeutic use
Viral infections
SummonAdditionalLinks – databaseName: Elsevier SD Freedom Collection
  dbid: .~1
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED9KYWMvY8u-vHZFg9GnOpFtWZIfR1lpBx2FtSNvwpZtSBlOaNJC-7C_vXeS7HS0W8cggcTRYUd3vruf7wvgU1GndalrRCdZ2sZCWR4XvFYIVYqiqXIrlAsXHH-Th2fi6zSfbsB-XwtDaZVB93ud7rR1ODIJuzlZzGaT79zZcj5NaFaWEoTbhVAk5eNfd9I8MjfcgxbHtHpdxTM5H1-VlsLXlOGlXQ9PsjEP26c_-Z_ODh28gOfBgWSf_TW-hI2mG8ETP1LyegRPj0OwfAS7J74t9fUeO11XWS332C47WTesRprRD8qJcYW5rCd_BTdHHRU9XKEzWrOZn2VyU7LwZ5hPBAm6kpVdjW98-RYnbN6yi2bROFpP4SSAoYvM-vpx5kskGbqgLKWdShSjR5bz7jWcHXw53T-Mw6SG2CKgW8WlalWthHBBusTaKs2ULag4U8pK5GWLBxCF4-eyToTVFL3krdCysLXWtsjewGY375p3wCQyHpEy16Ii5aK1pFCzyBurq0SqNgLR88fY0Macpmn8NH2-2rkJO2GIrYYrg2yNYDyQLXwfj8cIZM980xepolo1aGkeI1QPETbLoByWJjHL1HBzT4Aj0APlb_fAv5x0u5dPM5wnReieohHhKoKPw8-oPigmVHbN_JLWIGBFn1Xkf1mTJBJhukpFBG-97A97mNEjMQTt7___2rfgGX1ziXv5NmyuLi6bD-jpraoddyvfAtWuT44
  priority: 102
  providerName: Elsevier
Title Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X18310740
https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X18310740
https://dx.doi.org/10.1016/j.vaccine.2018.07.065
https://www.ncbi.nlm.nih.gov/pubmed/30093289
https://www.proquest.com/docview/2094288707
https://www.proquest.com/docview/2087589345
https://www.proquest.com/docview/2116924724
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZoKxAXBMsrUCojoZ6aJU6c2DmhUrXagrpaQYv2ZiV2IlGhZGm2ldoDv50Z20kupUXaR7SbUR7jjL_P8yLkQ25iU0gD7CSJ65ALHYV5ZARQlTyvylRzYd0FJ_Nsdsa_LNOlX3DrfFhlbxOtoTatxjVyIOk5IGUYXeLT6neIXaPQu-pbaGyQLSxdhqNaLMUY4pHYxh5AM3jIWbQcM3g-nk-vCo2ua4zukrZ-J84vt89N_8Kedg46ekqeePBI9522n5EHVTMhD107yesJeXTiHeUTsrtwJamv9-jpmGHV7dFduhiLVYPM5AfGw9ikXNqLPyc3xw0mPFwBEDX0p-tjclNQfzHUBYF4O0mLxsAbXq68CW1relGtKivrJKz2KcBj2ueOU5ceSQF-0hjvFBMUlyvb5gU5Ozo8PZiFvktDqIHMrcNC1MIIzq2DjmldxonQOSZmZlnJ06KGH4CBw3ZhGNcSPZdRzWWWayOlzpOXZLNpm-o1oZmuDLDkSPISDYuUGbqZeVppWbJM1AHhvX6U9iXMsZPGL9XHqp0rfycUqlVFQoFaAzIdxFauhsd9AlmvfNUnqIJJVTDL3CcobhOsOm8YOsVUF6tIfY8sEI2WDBu9wSUHRA6SHvs4TPM_B93ux6cajjM-LgF5P_wNpgP9QUVTtZe4D5BVwKs8vWMfxjKg6CLmAXnlxv5wDxNcDgPC_ubuE3hLHuPZ2sC8dJtsri8uq3eA5NblDtmY_mE79qGFT3kA21v7x19nc_j-fDhffPsLiqxKYA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9NQ3y8IChfhQFGgj0tI0md2HlACA2mlq3TJDrUN5PYjsSEkrJ2Q90fxd_InZ2kPIyNl0mpFKU5JfGdz7_zfQG8zkxscmnQOhnEZcCFDoMsNAJNlSyzRaK5cO6C8UE6POKfp8l0DX63uTAUVtnqRKeoTa1pjxyN9AyRMkqXeD_7GVDXKPKuti00vFjs2eUvNNnm70Yfkb9v4nj302RnGDRdBQKNxsciyEUpjODcOZQirYt4IHRGiYRpWvAkL_ECWox4npuIa0metrDkMs20kVJT8SVU-Tf4AKcmZabv_BVSMnCNRNCs4QGPwukqY-jt8fZZrslVTtFk0tULpfXs4rXwX1jXrXm79-BuA1bZBy9d92HNVj246dtXLntwa9w45nuweehLYC-32GSV0TXfYpvscFUcG2l6Xyn-xiUBs5b8AZyPKkqwOEPga9h33zflPGfNxzAfdNLoZZZXBn94-HIqrC7ZiZ1ZR-spnLQxhOOszVVnPh2TIdxlMY1UJBhtj9bVQzi6Fv49gvWqruwTYKm2Bq3yUPKCFJmUKbm1eWK1LKJUlH3gLX-UbkqmU-eOH6qNjTtWzUgoYqsKhUK29mG7I5v5miFXEaQt81WbEIsqXOGqdhWhuIjQzhtFNFeRmscqVF9CB3zDaUSN5fCT-yA7ygZreQz1Pw_daOVTdc9ZTc8-vOr-RlVF_qe8svUp3YPGMeJjnlxyTxSlWcxFzPvw2Mt-N4YD2n6LZfb08hd4CbeHk_G-2h8d7D2DO_TmLigw2YD1xcmpfY4oclG8cFOXwbfr1hV_AFoegAA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9NQ0y8IChfhQFGgj0tW5I6sfOAENqoVsamSmyob15iOxITSsrSDXV_Gn8dd3bS8jA2XialUpTmlMR3Pv_O9wXwNjOxyaVB62QQlwEXOgyy0Ag0VbLMFonmwrkLDg7TvWP-eZJMVuB3lwtDYZWdTnSK2tSa9sjRSM8QKaN0ie2yDYsY7w4_TH8G1EGKPK1dOw0vIvt2_gvNt-b9aBd5_S6Oh5-OdvaCtsNAoNEQmQW5KIURnDvnUqR1EQ-EziipME0LnuQlXkDrEc9zE3EtyesWllymmTZSairEhOr_jhgISXNM7vwVXjJwTUXQxOEBj8LJMnto-3TrItfkNqfIMulqh9LadvW6-C_c69a_4QO43wJX9tFL2kNYsVUP7vpWlvMerB20TvoebIx9Oez5JjtaZnc1m2yDjZeFspGm941icVxCMOvIH8HlqKJkiwsEwYZ99z1ULnPWfgzzASitjmZ5ZfCHhy-twuqSndmpdbSewkkeQ2jOurx15lMzGUJfFtNIRYLRVmldPYbjW-HfE1it6so-A5Zqa9BCDyUvSKlJmZKLmydWyyJKRdkH3vFH6bZ8OnXx-KG6OLlT1Y6EIraqUChkax-2FmRTXz_kJoK0Y77qkmNRnStc4W4iFFcR2qZVSo2KVBOrUH0NHQgOJxE1mcNP7oNcULa4y-Op_3noeiefavGc5VTtw5vF36i2yBeVV7Y-p3vQUEaszJNr7omiNIu5iHkfnnrZX4zhgLbiYpk9v_4FXsMaagn1ZXS4_wLu0Yu7-MBkHVZnZ-f2JQLKWfHKzVwGJ7etKv4AllCENg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inactivated+influenza+vaccine+effectiveness+and+an+analysis+of+repeated+vaccination+for+children+during+the+2016%2F17+season&rft.jtitle=Vaccine&rft.au=Shinjoh%2C+Masayoshi&rft.au=Sugaya%2C+Norio&rft.au=Yamaguchi%2C+Yoshio&rft.au=Iibuchi%2C+Noriko&rft.date=2018-09-05&rft.issn=0264-410X&rft.volume=36&rft.issue=37&rft.spage=5510&rft.epage=5518&rft_id=info:doi/10.1016%2Fj.vaccine.2018.07.065&rft.externalDBID=ECK1-s2.0-S0264410X18310740&rft.externalDocID=1_s2_0_S0264410X18310740
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X18X0036X%2Fcov150h.gif